Plasma cell leukemia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma (MM). It is characterized by the presence of a large number of circulating clonal plasma cells. It is comprised of two forms: (1) primary PCL (pPCL) which originate de novo with no prior history of MM and (2) secondary PCL (sPCL) where patients with a prior history of MM develop a leukemic phase of their MM. The natural history of either form of PCL is quite aggressive compared with MM. The incorporation of novel agent therapies and high-dose chemotherapy followed by stem cell rescue has made modest improvement in survival outcomes of patients with PCL over the last decade. Future, clinical trials incorporating various combinations of novel and experimental therapeutics are still warranted for the management of this disease.

Original languageEnglish (US)
Title of host publicationBiology and Management of Unusual Plasma Cell Dyscrasias
PublisherSpringer New York
Pages1-16
Number of pages16
ISBN (Electronic)9781441968487
ISBN (Print)9781441968470
DOIs
StatePublished - Jan 1 2016

Fingerprint

Plasma Cell Leukemia
Multiple Myeloma
Disease Management
Plasma Cells
Natural History
Stem Cells
Clinical Trials
Drug Therapy
Survival
Therapeutics

Keywords

  • Circulating plasma cells
  • Extramedullary myeloma
  • Plasma cell leukemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gonsalves, W., & Kumar, S. K. (2016). Plasma cell leukemia. In Biology and Management of Unusual Plasma Cell Dyscrasias (pp. 1-16). Springer New York. https://doi.org/10.1007/978-1-4419-6848-7_1

Plasma cell leukemia. / Gonsalves, Wilson; Kumar, Shaji K.

Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York, 2016. p. 1-16.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gonsalves, W & Kumar, SK 2016, Plasma cell leukemia. in Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York, pp. 1-16. https://doi.org/10.1007/978-1-4419-6848-7_1
Gonsalves W, Kumar SK. Plasma cell leukemia. In Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York. 2016. p. 1-16 https://doi.org/10.1007/978-1-4419-6848-7_1
Gonsalves, Wilson ; Kumar, Shaji K. / Plasma cell leukemia. Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York, 2016. pp. 1-16
@inbook{4d967b1c247647cb89951bafe2563a03,
title = "Plasma cell leukemia",
abstract = "Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma (MM). It is characterized by the presence of a large number of circulating clonal plasma cells. It is comprised of two forms: (1) primary PCL (pPCL) which originate de novo with no prior history of MM and (2) secondary PCL (sPCL) where patients with a prior history of MM develop a leukemic phase of their MM. The natural history of either form of PCL is quite aggressive compared with MM. The incorporation of novel agent therapies and high-dose chemotherapy followed by stem cell rescue has made modest improvement in survival outcomes of patients with PCL over the last decade. Future, clinical trials incorporating various combinations of novel and experimental therapeutics are still warranted for the management of this disease.",
keywords = "Circulating plasma cells, Extramedullary myeloma, Plasma cell leukemia",
author = "Wilson Gonsalves and Kumar, {Shaji K}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-6848-7_1",
language = "English (US)",
isbn = "9781441968470",
pages = "1--16",
booktitle = "Biology and Management of Unusual Plasma Cell Dyscrasias",
publisher = "Springer New York",

}

TY - CHAP

T1 - Plasma cell leukemia

AU - Gonsalves, Wilson

AU - Kumar, Shaji K

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma (MM). It is characterized by the presence of a large number of circulating clonal plasma cells. It is comprised of two forms: (1) primary PCL (pPCL) which originate de novo with no prior history of MM and (2) secondary PCL (sPCL) where patients with a prior history of MM develop a leukemic phase of their MM. The natural history of either form of PCL is quite aggressive compared with MM. The incorporation of novel agent therapies and high-dose chemotherapy followed by stem cell rescue has made modest improvement in survival outcomes of patients with PCL over the last decade. Future, clinical trials incorporating various combinations of novel and experimental therapeutics are still warranted for the management of this disease.

AB - Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma (MM). It is characterized by the presence of a large number of circulating clonal plasma cells. It is comprised of two forms: (1) primary PCL (pPCL) which originate de novo with no prior history of MM and (2) secondary PCL (sPCL) where patients with a prior history of MM develop a leukemic phase of their MM. The natural history of either form of PCL is quite aggressive compared with MM. The incorporation of novel agent therapies and high-dose chemotherapy followed by stem cell rescue has made modest improvement in survival outcomes of patients with PCL over the last decade. Future, clinical trials incorporating various combinations of novel and experimental therapeutics are still warranted for the management of this disease.

KW - Circulating plasma cells

KW - Extramedullary myeloma

KW - Plasma cell leukemia

UR - http://www.scopus.com/inward/record.url?scp=85006355017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006355017&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-6848-7_1

DO - 10.1007/978-1-4419-6848-7_1

M3 - Chapter

SN - 9781441968470

SP - 1

EP - 16

BT - Biology and Management of Unusual Plasma Cell Dyscrasias

PB - Springer New York

ER -